BridgeMD
Assessment of short immunotherapy after radical surgery of high-risk malignant melanoma
EU CTIS ID: 2023-509994-22-00
What this study is testing
To assess whether adjuvant treatment with immunotherapy for 6 months is as effective as 12 months in patients with stage IIb-c, III and IV cutaneous malignant melanoma.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1) Performance status WHO 0-1. 2) Radical surgery for cutaneous malignant melanoma stage IIb-c, III and IV.
You likely can't join if
- 1) The patient is assessed as unfit to receive systemic adjuvant treatment. 2) An active, known, or suspected autoimmune disease.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.